CINECA IRIS Institutional Research Information System

GASCO, Alberto
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.855
EU - Europa 7.120
AS - Asia 3.604
AF - Africa 82
SA - Sud America 46
OC - Oceania 39
Continente sconosciuto - Info sul continente non disponibili 17
Totale 21.763
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.683
CN - Cina 1.885
DE - Germania 1.128
IT - Italia 996
SE - Svezia 951
IE - Irlanda 858
UA - Ucraina 675
SG - Singapore 667
FR - Francia 546
GB - Regno Unito 480
FI - Finlandia 467
KR - Corea 362
AT - Austria 294
VN - Vietnam 265
PL - Polonia 260
CA - Canada 159
DK - Danimarca 147
IN - India 123
RU - Federazione Russa 72
JP - Giappone 69
ID - Indonesia 65
BE - Belgio 61
SN - Senegal 52
TW - Taiwan 50
NL - Olanda 43
GR - Grecia 42
ES - Italia 31
AU - Australia 29
BR - Brasile 25
TR - Turchia 23
HK - Hong Kong 20
EU - Europa 17
CH - Svizzera 16
EG - Egitto 15
IR - Iran 15
UZ - Uzbekistan 15
MX - Messico 11
RO - Romania 10
NZ - Nuova Zelanda 9
BG - Bulgaria 8
JO - Giordania 8
CL - Cile 7
NO - Norvegia 7
MU - Mauritius 6
HR - Croazia 5
HU - Ungheria 5
LT - Lituania 5
TH - Thailandia 5
CZ - Repubblica Ceca 4
IL - Israele 4
MY - Malesia 4
PE - Perù 4
PK - Pakistan 4
ZA - Sudafrica 4
CO - Colombia 3
CY - Cipro 3
IQ - Iraq 3
PT - Portogallo 3
SA - Arabia Saudita 3
UY - Uruguay 3
AM - Armenia 2
AR - Argentina 2
EC - Ecuador 2
MA - Marocco 2
PA - Panama 2
PH - Filippine 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
AE - Emirati Arabi Uniti 1
IM - Isola di Man 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MO - Macao, regione amministrativa speciale della Cina 1
MW - Malawi 1
PW - Palau 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
Totale 21.763
Salva come PNG Salva come JPEG
Città #
Chandler 1.347
Ann Arbor 1.120
Beijing 1.081
Dublin 853
Fairfield 677
Santa Clara 582
Singapore 519
Ashburn 510
Jacksonville 435
Houston 367
Dearborn 363
Woodbridge 363
Villeurbanne 305
Wilmington 302
Seattle 297
Vienna 288
Princeton 278
Torino 264
Medford 255
Nyköping 255
Warsaw 253
Dong Ket 223
Cambridge 216
Frankfurt am Main 197
Columbus 190
Pisa 190
Munich 108
Fremont 101
Redwood City 99
Milan 98
Boston 86
Boardman 76
Shanghai 73
Guangzhou 65
Jakarta 63
Nanjing 61
Brussels 58
Hangzhou 52
Verona 51
Toronto 49
Ottawa 47
Helsinki 44
Taipei 42
Falls Church 41
Norwalk 41
San Diego 37
Shenyang 36
Lachine 33
Zhengzhou 32
Hefei 31
Düsseldorf 28
Washington 28
New York 27
Jinan 25
Pune 25
Turin 25
Kharkiv 20
Kunming 20
Monmouth Junction 20
Phoenix 20
Philadelphia 19
Tokyo 19
Wuhan 19
Chengdu 17
Nürnberg 17
Los Angeles 16
Nanchang 16
Siena 16
Toledo 15
Nuremberg 14
Silver Spring 14
Hebei 13
Nottingham 13
Rome 13
Lansing 12
Cairo 11
Changsha 11
Copenhagen 11
Leinì 11
London 11
Mountain View 11
Xian 11
Bologna 10
Des Moines 9
Fuzhou 9
Tianjin 9
Ardabil 8
Buffalo 8
Dallas 8
Mumbai 8
Tappahannock 8
West Jordan 8
Cardiff 7
Catania 7
Florence 7
Hong Kong 7
Leawood 7
Naples 7
Amsterdam 6
Dresden 6
Totale 13.841
Salva come PNG Salva come JPEG
Nome #
Quinone based nitric oxide donating compounds 555
1,2,5-Oxadiazole analogues of leflunomide and related compounds 444
H2S-Donating Doxorubicins May Overcome Cardiotoxicity and Multidrug Resistance 416
1,1-Dinitroethyl substituted furoxans : a new class of vasodilators and inhibitors of platelet aggregation 354
Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells 311
Hyaluronated liposomes containing H2S-releasing doxorubicin are effective against P-glycoprotein-positive/doxorubicin-resistant osteosarcoma cells and xenografts 306
Light-Regulated NO Release as a Novel Strategy To Overcome Doxorubicin Multidrug Resistance 298
New furoxan derivatives for the treatment of ocular hypertension 285
Doxorubicin-antioxidant multitarget drugs 278
Designing Multitarget Anti-inflammatory Agents: Chemical Modulation of the Lumiracoxib Structure toward Dual Thromboxane Antagonists-COX-2 Inhibitors. 270
NO-donor thiacarbocyanines as multifunctional agents for Alzheimer’s disease 265
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors 257
New inhibitors of dihydroorotate dehydrogenase (DHODH) based on the 4-hydroxy-1,2,5-oxadiazol-3-yl (hydroxyfurazanyl) scaffold 252
A new series of amodiaquine analogues modified in the basic side chain with in vitro antileishmanial and antiplasmodial activity 234
Edaravone derivatives containing NO-donor functions 221
Carnosine analogues containing NO-donor substructures: Synthesis, physico-chemical characterization and preliminary pharmacological profile 219
A Molecular Hybrid for Mitochondria-Targeted NO Photodelivery 210
4-Hydroxy-1,2,5-oxadiazol-3-yl Moiety as Bioisoster of the Carboxy Function. Synthesis, Ionization Constants, and Molecular Pharmacological Characterization at Ionotropic Glutamate Receptors of Compounds Related to Glutamate and Its Homologues 205
1,4-Dihydropyridines containing R-NNO-azoxy moieties 199
(Nitrooxyacyloxy)methyl esters of aspirin as novel nitric oxide releasing aspirins 199
Phenylsulfonylfuroxans as Modulators of Multidrug-Resistance-Associated Protein-1 and P-Glycoprotein 188
New nitric oxide or hydrogen sulfide releasing aspirins 177
Synthesis physicochemical profile and PAMPA study of new NO-donor edaravone co-drugs 174
Composti ibridi per il trattamento della malaria cerebrale 173
Amodiaquine analogues containing NO-donor substructures: Synthesis and their preliminary evaluation as potential tools in the treatment of cerebral malaria 172
A Nonmetal-Containing Nitric Oxide Donor Activated with Single-Photon Green Light 167
Development of a new class of potential antiatherosclerosis agents: NO-donor antioxidants 164
Novel nitro-oxy derivatives of celecoxib for the regulation of colon cancer cell growth 162
Combination of PDT and NOPDT with a tailored BODIPY derivative 161
Effects of Nitric Oxide Donor Antioxidants Containing the Phenol Vitamin E Substructure and a Furoxan Moiety on Ischemia/Riperfusion Injury 158
Synthesis and preliminary biological profile of new NO-donor tolbutamide analogues. 158
Light-Tunable Generation of Singlet Oxygen and Nitric Oxide with a Bichromophoric Molecular Hybrid: a Bimodal Approach to Killing Cancer Cells 157
4-Methyl-3-(arylsulfonyl)furoxans: a new class of potent inhibitors of platelet aggregation. 152
Nitrooxymethyl Substituted Analogues of Celecoxib: Synthesis and Pharmacological Characterization 146
Synthesis and biological evaluation of the first example of NO-donor histone deacetylase inhibitor 144
Nitrooxymethyl-Substituted Analogues of Rofecoxib: Synthesis and Pharmacological Characterization 141
A multi-photoresponsive molecular-hybrid for dual-modal photoinactivation of cancer cells 140
NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties 138
Multitarget Drugs: Synthesis and Preliminary Pharmacological Characterization of Zileuton Analogues Endowed with Dual 5-LO Inhibitor and NO-Dependent Activities 138
A new class of NO-donor H3-Antagonists 135
Searching for new NO-donor aspirin-like molecules: furoxanylacyl derivatives of salicylic acid and related furazans 135
Synthesis and preliminary pharmacological characterisation of a new class of nitrogen-containing bisphosphonates (N-BPs) 134
Amphiphilic NO-Donor Antioxidants 134
Water-Soluble Nitric-Oxide-Releasing Acetylsalicylic Acid (ASA) Prodrugs 132
Activation of endothelial guanylate cyclase inhibits cellular reactivity. 131
Searching for new NO-donor Aspirin-like molecules: a new class of nitrooxy-acyl derivatives of salicylic acid 131
Fluorescent Nitric Oxide Photodonors Based on BODIPY and Rhodamine Antennae 130
Novel R-roscovitine NO-donor hybrid compounds as potential pro-resolution of inflammation agents 128
Multitarget Drugs: Focus on the NO-donor hybrid drugs 127
NO-Donor Melatonin Derivatives: Synthesis And In Vitro Pharmacological Characterization 127
Nitric Oxide Donor Doxorubicins Accumulate into Doxorubicin-Resistant Human Colon Cancer Cells Inducing Cytotoxicity 126
Novel Antioxidant Agents Deriving From Molecular Combination of Vitamin C and NO-donor moieties 124
Use of Nitric Oxide Releasing Furoxan System in the Design of "Hybrids": Substitution of Furoxan Moieties for the Furan Ring in Prazosin 123
New praziquantel derivatives containing NO-donor furoxans and related furazans as active agents against Schistosoma mansoni 122
NO-donors: focus on furoxan derivatives 119
A molecular hybrid producing simultaneously singlet oxygen and nitric oxide by single photon excitation with green light 118
Synthesis of Some Novel Organic Nitrates and Comparative in Vitro Study of Their Vasodilator Profile 116
Tuning the Hydrophobicity of a Mitochondria-Targeted NO Photodonor 116
Carnosine analogues containing Phenol substructures 114
Synthesis, physico-chemical characterization, andbiological activities of new carnosine derivatives stablein human serum as potential neuroprotective agents 113
SAR STUDIES ON H2 ANTAGONISTS CONTAINING ALKYLAMINO SUBSTITUTED 1,2,5-THIADIAZOLE 1-OXIDE MOIETIES 111
NO-Donor Phenols: A New Class of Products Endowed with Antioxidant and Vasodilator Properties 109
ALPHA(1)-ADRENOCEPTOR BLOCKING ACTIVITY OF SOME RING-OPEN ANALOGS OF PRAZOSIN 107
Inhibition of Human Placenta Glutathione Transferase P1-1 by the Antibiotic Calvatic Acid and its Diazocyanide Analogue: Evidence for Multiple Catalytic Intermediates 106
Endoplasmic reticulum-targeting doxorubicin: a new tool effective against doxorubicin-resistant osteosarcoma 106
Characterization of a new compound, S35b, as a guanylate cyclase activator in human platelets. 104
New potential uroselective NO-donor a1-antagonists 104
A new furoxan NO-donor rabeprazole derivative and related compounds 103
Activité contre les Microorganismes de dex Pyrazolyldiazène carbonitriles Oxyde-2 103
Different multitarget approaches to manage coxibs associatedcardiovascular risk. Design and synthesis of new lumiracoxibderivatives 103
Synthesis and Structure of a Trimer of the Furoxan System with High Vasodilator and Platelet Antiaggregatory Activity 103
Synthesis and pharmacological characterisation of new H2-antagonists containing NO-donor moieties, endowed with mixed antisecretory and gastroprotective activities. 103
Nitrooxyacyl Derivatives of Salicylic Acid: Aspirin-Like Molecules that Covalently Inactivate Cyclooxygenase-1 103
A new class of ibuprofen derivatives with reduced gastrotoxicity 102
A novel hybrid aspirin-NO releasing compound inhibits TNFalpha release from LPS-activated human monocytes and macrophages 102
[3-(1H-Imidazol-4-yl)propyl)guanidines Containing Furoxan Moieties: A New Class of H3-Antagonists Endowed with NO-Donor Properties 101
DNA-targeted NO release photoregulated by green light 99
Anti-Helicobacter pylori Agents Endowed with H2-antagonist Properties 98
Furoxan analogues of the histamine H3-receptor antagonist imoproxifan and related furazan derivatives 98
6-Cyclohexylmethoxy-5-(cyano-NNO-azoxy)pyrimidine-4-amine: A new scaffold endowed with potent CDK2 inhibitory activity 98
Characterisation of Furoxancarbonitriles as a New Class of Vasodilators 98
Identification of 2,3-diaminophenazine and of o-benzoquinone dioxime as the major in vitro metabolites of benzofuroxan 98
Activity of calvatic acid and its analogs against Helicobacter pylori 95
A multitarget approach to optimize the safety profile of coxibs: lumiracoxib derivatives with dual cyclooxygenase-2 inhibitor-thromboxane A2 receptor antagonist activity 95
A Directed Synthesis of Alkyl, Aryl, and Heteroaryl-ONN-azoxycyanides 94
Unsymmetrically Substituted Furoxans. VII. A 13C NMR Study of a Series of Isomeric Pairs of Furoxans and the Structure of the two Isomeric Chlorophenyl furoxans 94
S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. 94
Oximation of Acetyl(hydroxyimino)acetone: Nuclear Magnetic Resonance Spectroscopic, Chemical, and X-Ray Crystallographic Studies of the Reaction Products 93
Furoxan derivatives as NO-donors 92
A NEW CLASS OF FUROXAN DERIVATIVES AS NO DONORS - MECHANISM OF ACTION AND BIOLOGICAL-ACTIVITY 92
Synthesis and antimalarial activities of some furoxan sulfones and related furazans 91
Novel Organic Nitrate Esters 90
NO-donor Carnosine Derivatives As Potential Neuroprotective Agents 90
WATER SOLUBLE FUROXAN DERIVATIVES AS NO PRODRUGS 89
Pharmacochemistry of the Furoxan Ring : Recent Developments 89
Searching for Balanced Hybrid NO-Donor 1,4-Dihydropyridines with Basic Properties 88
Glutathione potentiates cGMP synthesis induced by the two phenylfuroxancarbonitrile isomers in RFL-6 cells. 88
NO-Donor Furoxans Containing a Sulphonamide Moiety and Related Furazans as Potent Carbonic Anhydrase Inhibitors 88
13C and 15N Solution and Solid-state Nuclear Magnetic Resonance Study of the Intermolecular interactions in the 1:1 Trimethoprim:Sulphamethoxazole Complex 88
Novel water soluble furoxan derivatives having antitumor activity 87
Totale 15.319
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.932
article - articoli 0
book - libri 0
conference - conferenze 8.730
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 70.662
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.289 0 0 0 0 0 497 410 193 388 367 237 197
2020/20212.297 211 159 167 107 175 141 154 119 345 193 139 387
2021/20223.161 153 131 175 248 231 68 292 212 103 307 648 593
2022/20233.662 446 364 105 380 280 882 400 207 321 83 119 75
2023/20241.398 171 223 102 75 115 194 51 56 17 84 101 209
2024/20251.975 56 275 169 380 877 218 0 0 0 0 0 0
Totale 22.477